FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation, and differentiation. The most clinically important point is that mutation of the FLT3 gene is the most frequent genetic alteration and poor prognostic factor in acute myeloid leukemia (AML) patients. FLT3 mutations consist of internal tandem duplication in the juxtamembrane domain (FLT3-ITD) and point mutation or deletion in the tyrosine kinase domain (FLT3-TKD). Both mutant FLT3 molecules are activated through ligand-independent dimerization and trans-phosphorylation. Mutant FLT3 induces activations of multiple intracellular signaling pathways, mainly STAT5, MAPK, and AKT signals, leading to cell proliferation and anti-apoptosis. Since high-dose chemotherapy and allogeneic hematopoietic stem cell transplantation cannot sufficiently improve the prognosis, clinical development of FLT3 kinase inhibitors has been strongly expected. Although several FLT3 inhibitors have been developed, it requires more than 20 years from the first identification of FLT3 mutations until FLT3 inhibitors become clinically available for AML patients with FLT3 mutations. To date, 3 FLT3 inhibitors have been clinically approved as monotherapy or combination therapy with conventional chemotherapeutic agents in Japan and/or Western countries. However, several mechanisms of resistance to FLT3 inhibitors have already become apparent during their clinical trials. The resistance mechanisms are complex and emerging resistant clones are heterogenous. Further basic and clinical studies are required to establish the best therapeutic strategy for AML patients with FLT3 mutations.